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Abstract. The aim of this study was to determine the risk factors in patients on clopidogrel anti-platelet therapy after 
acute myocardial infarction, for cardiovascular mortality, re-hospitalization and admission to emergency care unit. We 
followed 175 patients on dual antiplatelet therapy, with clopidogrel and acetylsalicylic acid, for 1 year after acute 
myocardial infarction, both STEMI and NSTEMI. Beside demographic and clinical characteristics, genetic ABCB1, 
CYP2C19 and CYP2C9 profile was analyzed using Cox-regression analysis. End-points used were: mortality, re-
hospitalization and emergency care visits, all related to cardiovascular system. During the accrual and follow-up period, 
8 patients (4.6%) died, mostly as a direct consequence of an acute myocardial infarction. Re-hospitalization was needed 
in 27 patients (15.4%), in nine patients (33.3%) with the diagnosis of re-infarction. Thirty-two patients (18.3%) were 
admitted to emergency care unit due to cardiovascular causes, up to 15 times during the follow-up. NSTEMI was an 
independent predictor of all three events registered (mortality OR=7.4, p<0.05; re-hospitalization OR=2.8, p<0.05); 
emergency care visit OR=2.4, p<0.05). Other significant predictors were related to kidney function (urea and creatinine 
level, creatinine clearance), co-morbidities such as arterial hypertension and decreased left ventricular ejection fraction, 
as well as clopidogrel dosing regimen. As a conclusion, it may be suggested that one of the most significant predictors of 
cardiovascular events (mortality, re-hospitalization and emergency care visits) is NSTEMI. Besides, clopidogrel 
administration according to up-to-date guidelines, with high loading doses and initial doubled maintenance doses, 
improves 1-year prognosis in patients with AMI. 
Key words: clopidogrel, acute myocardial infarction, cardiovascular outcome. 
Introduction

 
Despite improvements in pharmacotherapy and man-
agement of patients with acute myocardial infarction, 
the mortality rate and the incidence of cardiovascular 
outcomes remain high. In Serbia, mortality is over 10%, 
partially due to low rate of primary PCI (22%), the most 
beneficial management option in these patients [1]. The 
rate of various cardiovascular events is the highest in 
the first month after the acute event, but remains signifi-
cant even a year after [2]. Cardiovascular diseases are 
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the most common cause of death in Serbia (53.3%), out 
of which 18.5% account for ischemic heart disease. 
More than a half of this mortality (54.0%) is caused my 
ACS. The highest number of newly diagnosed AMI is 
among patients older than 75 (34.1%), in both genders. 
Male and female gender ratio is 1:1.6. The overall inci-
dence rate is 232.2 (or 107.7 when standardized to the 
world population). The Nis region is characterized with 
very low standardized incidence rate (below 105.0), but 
with moderate mortality rate (31.3), the same as the 
country’s average [1]. The majority of the patients with 
AMI are treated according to the evidence-based guide-
lines. Nevertheless, pharmacogenetic factors may alter 
the medication efficacy and worsen the outcome in 
these patients. Besides, the risk of various cardiovascu-
lar events is associated with age and other patients’ 
characteristics, medical history and revascularization 
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method [2]. The rate of re-hospitalizations in a 30-day 
period goes up to 20% [3,4] in about a quarter due to 
cardiovascular causes [3]. After 3 months, the rate rises 
to 9.3%, and up to 20.2% after a year. Revascularization 
is needed in approximately 5% [5]. Known predictors 
are female sex, CABG surgery or PCI, prior ICD, vas-
cular disease, chronic kidney disease, diabetes mellitus, 
rheumatic valvular disease, chronic pulmonary disease 
and anemia [57]. 
Beside patients’ characteristics and co-morbidities, 
primarily decreased, but increased clopidogrel efficacy, 
as well, may be the reason of poor clinical outcome. P-
glycoprotein is a transporter involved in the absorption 
process of various drugs prescribed in patients with 
AMI. The presence of polymorphic T allele of ABCB1 
gene may alter their bioavailability, and their pharma-
codynamics effects. The absorption of clopidogrel, used 
in combination with acetylsalicylic acid as dual anti-
aggregation therapy, is impaired in ABCB1 TT homozy-
gotes, which may account for more than 25% in Cauca-
sians [8]. Besides, interactions with proton-pump-inhib-
itors prescribed for gastroprotection, carvedilol (and 
some other ACE-inhibitors), statins and calcium-chan-
nel blockers, via P-glycoprotein inhibition are possible 
[9]. Other polymorphisms of importance are on the 
genes encoding cytochrome P450 enzymes, particularly 
CYP2C19 and CYP2C9. Both of them are involved in 
the clopidogrel transformation into active metabolite. 
The induction or inhibition of these enzymes, as well as 
the other CYP involved in clopidogrel biotransfor-
mation, such as CYP3A4, may lay in the basis of sig-
nificant drug interactions [10]. 
The aim of this study was to determine the risk fac-
tors in patients on clopidogrel anti-platelet therapy after 
acute myocardial infarction, for cardiovascular mortal-
ity, re-hospitalization and admission to emergency care 
unit. 
Subjects and Methods 
The study was approved by Ethics Committee of the 
University of Niš, Faculty of Medicine. All the subjects 
were treated in accordance with the Declaration of Hel-
sinki. Before being recruited, each patient gave an in-
formed consent. It was designed as a prospective cohort 
study. 
Patients included in the study were treated at the Clinic 
of Cardiology, Clinical Center Niš, Serbia. They were 
recruited upon acute coronary syndrome with/without ST-
elevation diagnosis with biochemical and electrocardio-
graphical confirmation. We followed 175 patients, both 
with STEMI (75.2%) and NSTEMI (20.9%). Half of the 
patients (49.7%) were treated with primary PCI. Thirty-six 
patients (20.6%) were revascularized with fibrinolytics 
administration, alteplase (18.9%) or streptokinase (1.7%). 
Among alteplase patients, 7(4.0%) underwent rescue PCI. 
Conventional therapy was applied to the rest 29.7% pa-
tients. 
Study group characteristics are shown in Table 1. 
There were 122 male (69.7%) and 53 female (30.3%) 
patients. Their age varied from 30 to 89 years (average 
60.80±11.33 years). 
Table 1 Baseline characteristics of the study patients 
group 
 mean ± SD        
Age (years) 60.81 ±    11.29 
Heart rate (1/min.) 79.60 ±    19.08 
Systolic blood pressure (mmHg) 130.92 ±    26.81 
Diastolic blood pressure (mmHg) 79.79 ±    16.02 
Ejection fraction (%) 50.77 ±    11.70 
End-systolic dimension (mm) 52.33 ±      6.55 
End-diastolic dimension (mm) 37.35 ±      8.07 
Right ventricular systolic pressure (mmHg) 34.82 ±    11.71 
Left atrial size (mm) 39.76 ±      5.59 
Body-mass index (kg/m2) 26.99 ±      3.91 
Cholesterol (mmol/l) 5.58 ±      1.37 
LDL (mmol/l) 3.62 ±      1.19 
HDL (mmol/l) 1.12 ±      0.58 
Triglycerides (mmol/l) 2.01 ±      2.68 
Hemoglobin (g/l) 138.91 ±    19.51 
Hematocrit (l/l) 0.41 ±      0.06 
Platelets (109/l) 253.03 ±    78.75 
Leukocytes (109/l) 11.82 ±    10.91 
Erythrocytes (1012/l) 4.69 ±      0.65 
AST (U/l) 138.52 ±  170.49 
ALT (U/l) 45.25 ±    49.47 
LDH (U/l) 934.33 ±  769.07 
Glucose(mmol/l) 8.28 ±      4.56 
Creatinine (µmol/l) 103.41 ±    44.72 
Creatinine clearance (ml/min.) 79.28 ±    25.71 
Urea (mmol/l) 6.76 ±      3.20 
Sodium (mmol/l) 136.33 ±    10.31 
Potassium (mmol/l) 4.33 ±      0.48 
CRP (mg/l) 18.28 ±    32.55 
Troponins (ng/l) 12.82 ±    28.47 
Creatine kinase (U/l) 1052.74 ±1403.40 
CKMB (U/l) 100.86 ±  126.35 
Fibrinogen (g/l) 4.63 ±      2.06 
 N         (%) 
Male 122 (69.7%) 
STEMI 135 (77.1%) 
Previous AMI 31 (17.7%) 
Hypertension 110 (62.9%) 
DM 49 (28.0%) 
Atrial fibrillation 16   (9.1%) 
Smoking 60 (34.3%) 
Pharmacological therapy was carried out according to 
the guidelines. All the patients received antiplatelet and 
anticoagulant drugs. Antiaggregation therapy was 
achieved with ASA (98.3%) and clopidogrel (100.0%). 
The therapy of AMI consisted of ACE inhibitors (68.4%), 
beta-blockers (75.4%), diuretics (20.6%), spironolactone 
(17.7%), calcium channel blocker (11.4%), amiodarone 
(10.3%), digoxin (6.3%), long-lasting vasodilators 
(24.6%) and trimetazidine (10.3%), as well. Besides, they 
were given lipid-lowering statins (94.3%), pantoprazole 
for gastroprotection (90.3%) and anxiolytics (33.7%). 
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Thirty-one patients (17.7%) had previous AMI (re-
infarction patients were excluded from the study). 
Among co-morbidities, 110 (62.9%) had HTA diag-
nosed for 11.29±8.61 years, while 49 (28.0%) suffered 
from diabetes mellitus type 2 for approximately 8.64±7.83 
years, and 16 patients (9.1%) had atrial fibrillation. 
Anamnestic data showed that one third of the patients 
(34.3%) were current smokers (former smokers were 
considered non-smokers). 
Accrual time was 1 year, while the follow-up time 
was 6 months. During that period patients were moni-
tored for reporting to the emergency unit, re-hospitali-
zations and mortality. Non-related non-cardiovascular 
events were not included into analysis. 
During the accrual and follow-up period, all the pa-
tients were genotyped for ABCB1 C34335T (rs1045642), 
CYP2C19*2 (rs4244285) and *17 (rs12248560), as well as 
CYP2C9*2 (rs1799853). From each collected whole blood 
sample, we have isolated genomic DNA manually. Using 
the PCR-RFLP (polymerase chain reaction-restriction 
fragment length polymorphism) method and specific 
primers (Table 2), before-mentioned small nuclear 
polymorphisms (SNPs) were detected. 
Statistical Package for Social Sciences (SPSS 16.0; 
Chicago, Ill., USA) was used for statistical data analy-
sis. Baseline characteristics are presented as frequencies 
or means with SDs. Quantitative variables were com-
pared between groups using Student’s t-test, while for 
qualitative variables Fisher’s exact test was performed. 
A p value <0.05 was considered to be a measure of sta-
tistical significance. Using Cox-regression, hazard ratios 
and 95% CIs were calculated, and therefore, potentiated 
the comparison of outcome occurrence between groups 
and the effect of each predictor. 
Results 
During the accrual and follow-up period, 8 patients 
(4.6%) died. In 6 cases it was the direct consequence of 
an acute myocardial infarction. The other two deaths 
both had cardiovascular cause: infective myocarditis 
and lower extremity thrombosis. They occurred between 
7 and 297 days after the recruitment. Re-hospitalization 
was needed in 27 patients (15.4%). Most of them were 
re-hospitalized only once during the follow-up period, 
while the maximum number of re-hospitalizations was 7 
in one case. Nine patients (33.3%) were re-hospitalized 
with the diagnosis of re-infarction. In one of the cases 
the re-infarction was caused by stent thrombosis. The 
symptoms of angina pectoris, stable (22.2%) or unstable 
(11.1%), were the reason for re-admission reported as 
well. Thirty-two patients (18.3%) were admitted to 
emergency care unit due to cardiovascular causes, up to 
15 times during the follow-up. 
ABCB1 C3435T genotyping was 100.0% successful, 
while in 51 patients (29.1%) we could not determine 
CYP2C19 and CYP2C9 polymorphism. The observed 
genotype frequencies did not deviate significantly from 
those expected at Hardy-Weinberg equilibrium (Table 3). 
Table 3 ABCB1 C3435T, CYP2C19 and CYP2C9 
genotype frequencies 
Gene Genotype N (f) χ2 (p) 
ABCB1 C3435T CC 41 (23.4%) 
0.658 (0.720)  CT 81 (46.3%) 
 TT 53 (30.3%) 
CYP2C19 PM 5   (4.0%) 
4.649 (0.460) 
 IM 33 (26.6%) 
 EM 46 (37.1%) 
 URM 40 (32.3%) 
CYP2C9 CC 115 (79.3%) 
4.634 (0.099)  CT 28 (19.3%) 
 TT 2   (1.4%) 
Table 2 Primers used for SNPs detection 
ABCB1 C3435T C (5'‑GGTGTCACAGGAAGAGATC‑3') 
 T (5'‑CAGCCGGGTATAGTCACAGGAAGATATT‑3') 
 Reverse (5'‑GGCCAGAGAGGCTGCCACAT‑3') 
CYP2C19*2 Forward (5'‑AATTACAACCAGAGCTTGGC‑3') 
 Reverse (5'‑TATCACTTTCCATAAAAGCAAG‑3') 
CYP2C19*17 Forward (5'‑GCCCTTAGCACCAAATTCTC‑3') 
 Reverse (5'‑ATTTAACCCCCTAAAAAAACACG‑3') 
CYP2C9*2 Forward (5'‑GTATTTTGGCCTGAAACCCATA‑3') 
 Reverse (5'‑GGCCTTGGTTTTTCTCAACTC‑3') 
Table 4 Cardiovascular outcomes in relation to genotype 
 Emergency care unit 
admission (HR (CI 95%), p) 
Re-hospitalization 
(HR (CI 95%), p) 
Cardiovascular death 
(HR (CI 95%), p) 
ABCB1 genotype (CC-CT-TT) 1.2 (0.7-1.9), 0.526 1.4 (0.9-2.5), 0.170 0.5 (0.2-1.4), 0.221 
ABCB1 TT genotype 0.9 (0.4-2.0), 0.866 1.3 (0.6-2.8), 0.556 0.3 (0.0-2.7), 0.298 
ABCB1 any T allele 1.8 (0.7-4.8 ), 0.216 2.7 (0.8-9.1), 0.102 0.5 (0.1-2.1), 0.348 
CYP2C19 phenotype (SM-IM-EM-URM) 0.8 (0.5-1.2), 0.245 0.9 (0.5-1.4), 0.528 0.8 (0.4-2.0), 0.694 
CYP2C19 any *2 allele 1.5 (0.7-3.3), 0.309 1.4 (0.6-3.4), 0.442 1.8 (0.4-7.9), 0.460 
CYP2C19 any *17 allele 0.8 (0.4-1.8 ), 0.612 1.0 (0.4-2.5 ), 0.885 0.5 (0.1-2.7). 0.448 
CYP2C9 any *2 allele 0.4 (0.1-1.3), 0.128 0.7 (0.2-2.1), 0.553 0.6 (0.1-5.4), 0.686 
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As genetic predictors, we have analyzed the presence 
of various genotypes and phenotypes of ABCB1, 
CYP2C19 and CYP2C9 genes. For each of the three 
outcomes monitored, none of the predictors were shown 
to be statistically significant (Table 4). 
We have tested the patients’ characteristics, co-mor-
bidities and social habits such as smoking as risk pre-
dictors of cardiovascular outcomes (Table 57). Even 
though univariate Cox-regression analysis have identi-
fied a number of statistically significant predictors of 
need for re-hospitalization (Table 5), after their inclu-
sion into a multivariate model (χ2=18.522, p<0.001), the 
only predictors that remained independently significant 
were the type of AMI, with or without ST-segment ele-
vation, and clopidogrel dosing regimen. Patients after 
NSTEMI had 2.8 higher risk (p<0.05) of re-hospitaliza-
tion due to cardiovascular indications. Patients with 
lower dose clopidogrel dosing regimens (lower or no 
loading dose) had 2.3 times higher risk of re-hospitali-
zation (p<0.05). 
Considering emergency care unit admission, due to 
cardiovascular symptoms and signs (Table 6), the major-
ity of predictors identified by univariate Cox-regression 
modeling, remained independently significant in the mul-
tivariate model (χ2=35.662, p<0.001). In comparison to 
STEMI, NSTEMI is associated with 2.4 times higher risk 
(p<0.05). High LDL (above 3mmol/l) leads to 2.5 times 
lower risk (p<0.05). Patients with decreased LVEF after 
AMI, below 45%, had 3 times (p<0.05) higher risk of 
need for emergence care. Increased creatinine concentra-
tion, for each 10µmol/l, increases the risk 1.1 times 
(p<0.001). Patients with HTA are at 3 times higher risk 
(p<0.05) of emergency care need. Among the drugs pre-
scribed, therapy with calcium channel blockers increased 
the risk by 2.8 times (p<0.05). 
Despite low mortality, we have identified (Table 7) 
two significant predictors in a multivariate Cox-
regression model (χ2=15.137, p<0.01). Acute myocardial 
infarction without ST-segment elevation was associated 
with 7.4 higher risk of cardiovascular mortality (p<0.05). 
The increase in urea concentration for each unit augments 
the risk 1.1 times (p<0.05). 
Table 6 Predictors of emergency care due to cardiovascular causes 
Emergency care unit admission 
(HR (CI 95%), p) 
Univariate Cox-regression Multivariate Cox-regression 
NSTEMI 3.071 (1.512-6.240), 0.007 2.379 (1.080-5.243), 0.031 
High LDL>3mmol/l 0.431 (0.205-0.907) 0.027 0.399 (0.181-0.881), 0.023 
EF<45% 2.395 (1.191-4.817), 0.014 3.044 (1.398-6.629), 0.005 
Creatinine (µmol/l) 1.009 (1.004-1.014), 0.001 1.011 (1.004-1.017), 0.001 
Urea (mmol/l) 1.152 (1.067-1.243), 0.000  
HTA 2.867 (1.179-6.969), 0.024 3.133 (1.200-8.180), 0.020 
Diuretic 2.479 (1.212-5.072), 0.013  
Calcium channel blocker 2.664 (1.151-6.168), 0.022 2.782 (1.000-7.738), 0.050 
Table 5 Predictors of re-hospitalization due to cardiovascular causes 
Re-hospitalization  
(HR (CI 95%), p) 
Univariate Cox-regression Multivariate Cox-regression 
Age (years) 1.041 (1.005-1.078), 0.024  
NSTEMI vs. STEMI 4.148 (1.948-8.829), 0.000 2.785 (1.102-7.038), 0.030 
High LDL>3mmol/l 0.407 (0.176-0.942), 0.036  
Hemoglobin (g/l) 0.982 (0.965-1.000), 0.047  
Leukocytes (109/l) 0.817 (0.679-0.983), 0.032  
AST (U/L) 0.994 (0.988-0.999), 0.032  
Creatinine (µmol/l) 1.006 (1.000-1.011), 0.035  
Urea (mmol/l) 1.095 (1.019-1.178), 0.014  
CK(U/L) 0.999 (0.999-1.000), 0.049  
Previous AMI 4.102(1.919-8.771), 0.000  
HTA 5.069 (1.526-16.835), 0.008    
DM type 2 2.214 (1.036-4.732), 0.040  
Clopidogrel loading dose (mg) 0.996 (0.994-0.998), 0.000  
Clopidogrel loading dose/BMI (mg∙m2/kg) 0.905 (0.838-0.977), 0.011  
Clopidogrel dosing regimen (mg) 2.356 (1.227-4.522), 0.010 2.284 (1.136-4.593), 0.020 
Carvedilol vs. Bisoprolol 3.060 (1.099-8.518), 0.032  
Diuretic 2.927 (1.358-6.308), 0.006  
Spironolactone 2.835 (1.298-6.192), 0.009  
Long lasting nitrates 2.557 (1.196-5.463), 0.015  
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Discussion 
After a 1-year follow-up of patients after AMI, 4.6% 
died, 15.4% were re-hospitalized and 33.3% visited 
emergency unit, all associated with cardiovascular 
events. These rates are slightly lower than those re-
ported in previous studies (1,3–5). One of the risk fac-
tors for poor clinical outcome, regarding all three events 
registered is NSTEMI. Compared to STEMI patients, 
NSTEMI patients are associated with 2.4 times higher 
risk of emergency care needed, 2.8 times higher risk of 
re-hospitalization, and even 7.4 times higher risk of 
cardiovascular death. It is suggested that STEMI pa-
tients are favored by rapid revascularization and more 
aggressive pharmacotherapy, resulting in lower rate of 
mortality and re-hospitalizations in 1-year period after 
AMI [11]. 
Elevated creatinine concentration was found to be 
and independent predictor of re-hospitalizations, while 
elevated urea concentration was associated with in-
creased risk of cardiovascular mortality. Patients with 
chronic kidney disease, especially those with more se-
vere stages, are less likely to be revascularized and pre-
scribed evidence-based therapy. On the other hand, they 
presented more often with bleeding complications. 
When summed up, this results in higher mortality rate, 
particularly in STEMI patients [12]. 
Higher clopidogrel dosing regimen was found to be 
associated with lower risk of re-hospitalizations. When 
higher clopidogrel doses are administered, the produc-
tion of clopidogrel active metabolite is multiplied, de-
spite some saturation of the pharmacokinetic processes 
involved [13]. In the elderly, no loading dose is recom-
mended, while lower loading dose is prescribed in pa-
tients administered fibrinolytics [14]. High loading dose 
gives the greatest benefit in the first days after AMI, but 
increased maintenance dose, recommended in the first 
week, significantly decreases the risk of major adverse 
cardiovascular events [15]. 
Hyperlipidemia is a known risk factor for ACS and 
for the worse prognosis after AMI [16]. Our results have 
shown that high LDL favored good prognosis, as found 
in similar studies [17]. This may be due to the therapy 
with statins. Beside lowering LDL, these drugs have a 
number of pleiotropic effects in atherosclerotic diseases. 
Statins may have antithrombotic effect, directly dimin-
ishing the possibility of various cardiovascular events, 
due to inhibited platelet and activation and procoagulant 
protein tissue factor expression [18]. Besides, there are 
significant changes in atherosclerotic plaque character-
istics in patients receiving statin therapy, concerning 
calcium and fibrous deposition, as well as its elastic 
membrane, thus stabilizing the plaque [19]. 
After suffering AMI, in a large number of patients 
there is a decrease in left ventricular EF. This worsening 
of the cardiac contractile function is one of the prog-
nostic factors for bad prognosis. The risk increases at 
least 3 times [17,20], as found in our results. Mild and 
severe left ventricular dysfunctions are associated with 
higher risk in patients with AMI, especially in combi-
nation with co-morbidities [21]. 
We have found patients with HTA to be at more 
than 3 times higher risk of suffering from cardiovascular 
symptoms during the follow-up period after AMI. In the 
previous studies, somewhat lower hazard risk ratio was 
found for these patients to experience major adverse 
cardiovascular events [22,23], but it may rise to 5 times 
higher risk in patients with unspecified chest pain [24]. 
Therefore, patients on antihypertensive drugs, such as 
calcium channel blockers, were associated with worse 
prognosis, as well. 
Although there are numerous studies suggesting the 
association between genetic profile, including cytochrome 
P450 enzymes and P-glycoprotein, and outcome in patients 
after AMI [2527], we have not obtained statistically 
significant results. This may be explained by insufficient 
number of events for such genetic analysis. Except for 
ABCB1 polymorphisms for P-glycoproteins, low-function 
genotypes are rare in the Caucasian population. 
 
Table 7 Predictors of cardiovascular mortality 
Cardiovascular mortality 
(HR (CI 95%), p) 
Univariate Cox-regression Multivariate Cox-regression 
NSTEMI 11.019 (2.223-54.615), 0.003    7.431 (1.371-40.267), 0.020   
LDL (mmol/l) 0.514 (0.281-0.940), 0.031  
High LDL>3mmol/l 0.217 (0.049-0.970), 0.046  
Hemoglobin (g/l) 0.966 (0.938-0.995), 0.021  
Creatinine (µmol/l) 1.009 (1.003-1.015), 0.004  
Creatinine clearance (ml/min.) 0.933 (0.886-0.983), 0.009  
Urea (mmol/l) 1.162 (1.073-1.257), 0.000 1.094 (1.001-1.195), 0.046 
Previous AMI 4.820 (1.205-19.277), 0.026    
Clopidogrel loading dose (mg) 0.994 (0.990-0.999), 0.016  
Clopidogrel dosing regimen (mg) 5.190 (1.166-23.107), 0.031    
Acetylsalicylic acid loading dose (mg) 0.993 (0.986-0.999), 0.034  
Calcium channel blocker 5.004 (1.195-20.946), 0.027    
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Conclusion 
As a conclusion, we may imply that one of the most 
significant predictor of cardiovascular events (mortality, 
re-hospitalization and emergency care visits) is 
NSTEMI. Besides, clopidogrel administration according 
to up-to-date guidelines, with high loading doses and 
initial doubled maintenance doses, improves 1-year 
prognosis in patients with AMI. 
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